Johnson & Johnson Innovation, an investment vehicle of US-based pharmaceutical company Johnson & Johnson, has added a total of 17 collaborations to its list, increasing the total to more than 200.
Among the recently inked agreements is a partnership between Johnson & Johnson subsidiary Janssen Pharmaceutica and university Karolinska Institutet, first reported earlier this month, which will support research commercialisation and spin-outs.
The agreements cover a wide range of conditions and diseases from dengue fever to hepatitis B to asthma and Crohn’s disease.
New agreements have been inked with Washington University’s Disease Interception Accelerator; University of Queensland’s tech transfer office UniQuest; University of the Witwatersand; University of Arizona’s research institute Bio5; and MaRs Innovation, which commercialises research for 15 Canada-based research institutes and universities.
The Lead Discovery Centre, which commercialises research from Germany-based research institutions and HiFiBio, which focuses on commercialisation of life sciences university research, are also joining Johnson & Johnson Innovation’s list of partners.
Johnson & Johnson will also collaborate with contract research and development company WuXi AppTec; biotechnology company Emulate; biotechnology companies Carna Biosciences and Brim Biotechnology; and biotechnology company Arcturus Therapeutics.
Paul Stoffels, chief scientific officer of Johnson & Johnson, said: “Johnson & Johnson Innovation is focused on bringing forward cutting-edge healthcare solutions that could extend and improve lives.
“The collaborations announced today aim to accelerate innovation at all stages of research and development.
“We are committed to working with researchers around the world to push the boundaries of what science and medicine can achieve to transform healthcare.”